Oncotelic Therapeutics (OTLC) Short Interest Ratio & Short Volume → Elon’s New Device is About to Shock the World (From InvestorPlace) (Ad) Free OTLC Stock Alerts $0.04 0.00 (0.00%) (As of 05/17/2024 ET) Add Compare Share Share Short InterestStock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest Oncotelic Therapeutics Short Interest DataCurrent Short Volume1,800 sharesPrevious Short Volume11,400 sharesChange Vs. Previous Month-84.21%Dollar Volume Sold Short$71.91Short Interest Ratio / Days to Cover0.0Last Record DateApril 30, 2024Outstanding Shares398,670,000 sharesPercentage of Shares Shorted0.00%Today's Trading Volume106,436 sharesAverage Trading Volume63,398 sharesToday's Volume Vs. Average168% Short Selling Oncotelic Therapeutics ? Sign up to receive the latest short interest report for Oncotelic Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatOTLC Short Interest Over TimeOTLC Days to Cover Over TimeOTLC Percentage of Float Shorted Over Time Ad Stansberry ResearchA letter is coming from the "Bureau of the Fiscal Service".Is your bank next? A powerful new trend is spreading like wildfire inside the US financial system. At least 41 banks are already involved. But the Federal Reserve predicts that number will grow fast.See if your bank is involved right here. Oncotelic Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/20241,800 shares $71.91 -84.2%N/A0 $0.04 4/15/202411,400 shares $468.54 +2,750.0%N/A0.1 $0.04 3/31/2024400 shares $14.39 -89.7%N/A0 $0.04 3/15/20243,900 shares $144.69 -75.2%N/A0.1 $0.04 2/29/202415,700 shares $554.21 -90.9%N/A0.1 $0.04 2/15/2024172,400 shares $6,637.40 +34.8%N/A0.9 $0.04 Get the Latest News and Ratings for OTLC and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Oncotelic Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/15/2024111,900 shares $4,420.05 +27,875.0%N/A1.2 $0.04 12/31/2023400 shares $15.30 No ChangeN/A0 $0.04 12/15/2023400 shares $15.76 No ChangeN/A0 $0.04 11/30/2023400 shares $16.28 -97.6%N/A0 $0.04 11/15/202316,700 shares $542.75 -58.2%N/A0 $0.03 10/31/202339,900 shares $1,312.71 +66.3%N/A0.1 $0.03 10/15/202324,000 shares $816.00 +1,400.0%N/A0.1 $0.03 9/30/20231,600 shares $49.60 -95.4%N/A0 $0.03 9/15/202334,500 shares $1,086.75 -52.7%N/A0.1 $0.03 8/31/202372,900 shares $1,909.98 +138.2%N/A0.2 $0.03 8/15/202330,600 shares $703.80 -4.7%N/A0.3 $0.02 7/31/202332,100 shares $767.19 -50.3%N/A0.1 $0.02 7/15/202364,600 shares $1,627.92 +12.0%N/A0.1 $0.03 6/30/202357,700 shares $1,442.50 +1,054.0%N/A0 $0.03 6/15/20235,000 shares $150.00 -79.8%N/A0 $0.03 5/31/202324,700 shares $768.17 +6,075.0%N/A0.1 $0.03 5/15/2023400 shares $14.76 -55.6%N/A0 $0.04 4/30/2023900 shares $37.80 +125.0%N/A0 $0.04 4/15/2023400 shares $20.40 -99.1%N/A0 $0.05 3/31/202342,900 shares $2,037.75 +164.8%N/A0.3 $0.05 3/15/202316,200 shares $920.16 No ChangeN/A0.1 $0.06 2/28/202316,200 shares $891.00 -57.7%N/A0.1 $0.06 2/15/202338,300 shares $2,106.50 +137.9%N/A0.1 $0.06 1/31/202316,100 shares $821.10 -68.2%N/A0.1 $0.05 1/15/202350,700 shares $2,940.60 +53.6%N/A0.2 $0.06 12/30/202233,000 shares $1,485.00 +11.9%N/A0.1 $0.05 12/15/202229,500 shares $1,416.00 +2,358.3%N/A0.1 $0.05 11/30/20221,200 shares $70.32 -86.8%N/A0 $0.06 11/15/20229,100 shares $682.50 -65.5%N/A0.1 $0.08 10/31/202226,400 shares $1,188.00 -58.8%N/A0 $0.05 10/15/202264,000 shares $3,744.00 -49.7%N/A0.2 $0.06 9/30/2022127,200 shares $8,522.40 +4,286.2%N/A0.3 $0.07 9/15/20222,900 shares $205.90 -62.8%N/A0 $0.07 8/31/20227,800 shares $630.24 -77.5%N/A0 $0.08The Presidential candidate you should REALLY be worried about (Ad)The Presidential candidate you should REALLY be worried about Most Americans are overlooking the seemingly impossible candidate that should worry you. It's not Biden… Trump… Newsom… or even Michelle. It's someone even worse. New evidence of a secret plan indicates he could soon return, and finish what he started.Get the full story right here. OTLC Short Interest - Frequently Asked Questions What is Oncotelic Therapeutics' current short interest? Short interest is the volume of Oncotelic Therapeutics shares that have been sold short but have not yet been closed out or covered. As of April 30th, investors have sold 1,800 shares of OTLC short. Learn More on Oncotelic Therapeutics' current short interest. Is Oncotelic Therapeutics' short interest increasing or decreasing? Oncotelic Therapeutics saw a decline in short interest in the month of April. As of April 30th, there was short interest totaling 1,800 shares, a decline of 84.2% from the previous total of 11,400 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Oncotelic Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Oncotelic Therapeutics: NeuroSense Therapeutics Ltd. (0.16%), Tonix Pharmaceuticals Holding Corp. (1.89%), Ceapro Inc. (0.00%), Vincerx Pharma, Inc. (5.98%), Flora Growth Corp. (1.40%), Edesa Biotech, Inc. (0.69%), FSD Pharma Inc. (1.00%), Pieris Pharmaceuticals, Inc. (1.12%), Talphera, Inc. (0.90%), Minerva Neurosciences, Inc. (0.47%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Oncotelic Therapeutics stock? Short selling OTLC is an investing strategy that aims to generate trading profit from Oncotelic Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Oncotelic Therapeutics? A short squeeze for Oncotelic Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of OTLC, which in turn drives the price of the stock up even further. How often is Oncotelic Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including OTLC, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: NeuroSense Therapeutics Short Interest Tonix Pharmaceuticals Short Interest Ceapro Short Interest Vincerx Pharma Short Interest Flora Growth Short Interest Edesa Biotech Short Interest FSD Pharma Short Interest Pieris Pharmaceuticals Short Interest Talphera Short Interest Minerva Neurosciences Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (OTCMKTS:OTLC) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingElon’s New Device is About to Shock the WorldInvestorPlaceMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders AllianceA once-in-a-century investment opportunityStansberry Research[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHe Is Giving Away BitcoinCrypto Swap Profits